2024-12-13 05:29:19
Dotinolole, a new drug used by Weicai to treat gout, was approved for marketing in China. On December 10th, Weicai China announced that its new urate reuptake inhibitor Dotinolole tablets (trade name: Youlesi) had been approved by National Medical Products Administration (NMPA) in China, and its indication was gout with hyperuricemia.Reserve Bank of Australia President Brock: The policy needs to be carefully considered. Recent data are mixed and somewhat weak.Saudi Arabia claims that Israel's actions in Syria have destroyed the opportunity to restore security.
China's 10-year government bond yield fell by 5 basis points to 1.855%, a record low.LI: In the 49th week of 2024 (12.2-12.8), the weekly sales volume of LI reached 12,600 vehicles, ranking first in the sales volume of new power brands in China market for 33 consecutive weeks.The researcher of Everbright Bank commented on China's import and export data in November: the export growth rate is stronger than seasonality, and foreign trade exports are expected to grow steadily in the next few months. Zhou Maohua, a macro researcher in the financial market department of Everbright Bank, told Wall Street that the export growth rate in November was stronger than seasonality, the import decline exceeded expectations (weaker than seasonality), the trade surplus expanded, and foreign trade contributed more to the economy in the fourth quarter. Due to the resilience of overseas demand, overseas foreign trade importers rushed to avoid tariffs and hoarded goods in advance, and the effects of policies such as stabilizing foreign trade appeared, driving export growth to exceed expectations; The decline in imports in November exceeded expectations, mainly due to the weak recovery of domestic demand, the cautious decision of enterprises to expand and increase import inventory, and the low prices of international energy and other commodities that depressed the overall import cost.
Research Report: In the third quarter, the installed capacity of traction inverters for electric vehicles in China accounted for 61% of the world. According to the latest research of TrendForce Jibang Consulting, the total installed capacity of traction inverters for electric vehicles in the third quarter of 2024 reached 6.87 million, which was 7% higher than that in the same period last year, but the growth rate has been reduced. In the competition pattern of first-class suppliers, BYD benefited from the hot sales of its models. In the third quarter, the installed market share of traction inverter increased by 1% to 18%, surpassing Denso of Japanese factory for the first time and becoming the company with the highest market share. The market share of Huichuan Technology has also increased to 6%, which shows that the competitiveness of China manufacturers in this field continues to increase. Generally speaking, China manufacturers, Japanese manufacturers and Tesla together account for half of the global installed capacity, while the influence of European and American manufacturers is gradually weakening. TrendForce Jibang Consulting indicated that the regional differentiation of traction inverters is becoming more and more obvious, with the installed capacity in China accounting for 61% of the global total. Under the pressure of shrinking market, Europe is actively reforming and cutting expenditure to enhance the competitiveness of the electric vehicle industry chain. In the short term, the stable demand in China market will continue to support the growth of traction inverter market. In the long run, if the European automobile industry chain can be successfully reformed, it will help boost the overall performance of the global traction inverter and electric vehicle market.Pakistan KSE-100 index rose 0.8% to 110,933.10.The turnover of Shanghai and Shenzhen stock markets exceeded 1.5 trillion yuan for the third consecutive trading day.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13